Revision as of 22:55, 11 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,609 edits ce← Previous edit | Latest revision as of 22:57, 11 December 2024 edit undoCitation bot (talk | contribs)Bots5,408,055 edits Altered issue. Formatted dashes. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar | ||
Line 69: | Line 69: | ||
== History == | == History == | ||
AZD-1134 reached ] prior to the discontinuation of its development.<ref name="AdisInsight" /> It was under development by ].<ref name="AdisInsight" /> Another selective serotonin 5-HT<sub>1B</sub> receptor antagonist, ], was also subsequently developed and studied by AstraZeneca.<ref name="ZhangZhouWang2011">{{cite journal | vauthors = Zhang M, Zhou D, Wang Y, Maier DL, Widzowski DV, Sobotka-Briner CD, Brockel BJ, Potts WM, Shenvi AB, Bernstein PR, Pierson ME | title = Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist | journal = J Pharmacol Exp Ther | volume = 339 | issue = 2 | pages = 567–578 | date = November 2011 | pmid = 21825000 | doi = 10.1124/jpet.110.174433 | url = }}</ref><ref name="VarnäsNybergKarlsson2011">{{cite journal | vauthors = Varnäs K, Nyberg S, Karlsson P, Pierson ME, Kågedal M, Cselényi Z, McCarthy D, Xiao A, Zhang M, Halldin C, Farde L | title = Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with AZ10419369 | journal = Psychopharmacology (Berl) | volume = 213 | issue = |
AZD-1134 reached ] prior to the discontinuation of its development.<ref name="AdisInsight" /> It was under development by ].<ref name="AdisInsight" /> Another selective serotonin 5-HT<sub>1B</sub> receptor antagonist, ], was also subsequently developed and studied by AstraZeneca.<ref name="ZhangZhouWang2011">{{cite journal | vauthors = Zhang M, Zhou D, Wang Y, Maier DL, Widzowski DV, Sobotka-Briner CD, Brockel BJ, Potts WM, Shenvi AB, Bernstein PR, Pierson ME | title = Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist | journal = J Pharmacol Exp Ther | volume = 339 | issue = 2 | pages = 567–578 | date = November 2011 | pmid = 21825000 | doi = 10.1124/jpet.110.174433 | url = }}</ref><ref name="VarnäsNybergKarlsson2011">{{cite journal | vauthors = Varnäs K, Nyberg S, Karlsson P, Pierson ME, Kågedal M, Cselényi Z, McCarthy D, Xiao A, Zhang M, Halldin C, Farde L | title = Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with AZ10419369 | journal = Psychopharmacology (Berl) | volume = 213 | issue = 2–3 | pages = 533–545 | date = February 2011 | pmid = 21234549 | doi = 10.1007/s00213-011-2165-z | url = }}</ref> However, this drug was later found to produce unexpected ].<ref name="ChangCiaccioSchroeder2014">{{cite journal | vauthors = Chang JC, Ciaccio P, Schroeder P, Wright L, Westwood R, Berg AL | title = Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor | journal = J Toxicol Pathol | volume = 27 | issue = 1 | pages = 31–42 | date = April 2014 | pmid = 24791065 | pmc = 4000071 | doi = 10.1293/tox.2013-0033 | url = }}</ref> | ||
==References== | ==References== |
Latest revision as of 22:57, 11 December 2024
Pharmaceutical compound
Clinical data | |
---|---|
Routes of administration | Unspecified |
Drug class | Serotonin 5-HT1B receptor antagonist |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H32FN5O4 |
Molar mass | 521.593 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
AZD-1134 is an investigational new drug that was being evaluated for the treatment of major depressive disorder and anxiety disorder but was never marketed. It is a selective serotonin 5-HT1B receptor antagonist.
Pharmacology
The drug has been found to increase serotonin levels in the dorsal hippocampus in animals and to increase serotonin turnover (as measured by 5-HIAA/serotonin ratio) in the cerebral cortex, hypothalamus, hippocampus, and striatum. Alone, AZD-1134 increased hippocampal serotonin levels to 179% of baseline, and in combination with the selective serotonin reuptake inhibitor (SSRI) citalopram, it increased levels to 950% of baseline. The increases in serotonin levels and turnover with AZD-1134 are presumably due to blockade of inhibitory presynaptic 5-HT1B autoreceptors. AZD-1134 administered alone produced antidepressant-like effects in animals.
History
AZD-1134 reached preclinical research prior to the discontinuation of its development. It was under development by AstraZeneca. Another selective serotonin 5-HT1B receptor antagonist, AZD-3783, was also subsequently developed and studied by AstraZeneca. However, this drug was later found to produce unexpected neurotoxicity.
References
- ^ "AZD 1134". AdisInsight. 31 March 2004. Retrieved 11 December 2024.
- ^ Hudzik T, Smolka J, Litwin L, Porrey T, Pierson E (2003). "P.1.016 In vivo pharmacology of AZD1134, a novel 5-HT1B antagonist". European Neuropsychopharmacology. 13: S181–S182. doi:10.1016/S0924-977X(03)91727-5.
- ^ Smagin GN, Song D, Cross AJ, Mrzljak (2003). "P.1.094 AZD1134, a high affinity 5-HT1B receptor antagonist activates serotonin turnover and release in guinea pig brain". European Neuropsychopharmacology. 13: S214. doi:10.1016/S0924-977X(03)91804-9.
- Maier DL, Sobotka-Briner C, Ding M, Powell ME, Jiang Q, Hill G, et al. (July 2009). "AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy". The Journal of Pharmacology and Experimental Therapeutics. 330 (1): 342–351. doi:10.1124/jpet.109.150722. PMID 19401496.
- Zhang M, Zhou D, Wang Y, Maier DL, Widzowski DV, Sobotka-Briner CD, et al. (November 2011). "Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist". J Pharmacol Exp Ther. 339 (2): 567–578. doi:10.1124/jpet.110.174433. PMID 21825000.
- Varnäs K, Nyberg S, Karlsson P, Pierson ME, Kågedal M, Cselényi Z, et al. (February 2011). "Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with AZ10419369". Psychopharmacology (Berl). 213 (2–3): 533–545. doi:10.1007/s00213-011-2165-z. PMID 21234549.
- Chang JC, Ciaccio P, Schroeder P, Wright L, Westwood R, Berg AL (April 2014). "Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor". J Toxicol Pathol. 27 (1): 31–42. doi:10.1293/tox.2013-0033. PMC 4000071. PMID 24791065.
This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it. |